A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer

Abstract

Gastrectomy has been widely used for the treatment of gastric cancer, and the severity of physiological and microbial disorders has greatly harmed the health of patients. In the present study, a probiotic combination containing Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis and Bacillus cereus was used to reduce the physiological disorders induced by gastrectomy via monitoring the blood index and microbial diversity using high-throughput sequencing. Our results indicated that the probiotic combination had significantly reduced the inflammation indexes (leukocyte) (p<0.05), while it markedly enhanced the immunity indexes (lymphocyte) and nutrition indexes (albumin and total protein) (p<0.05). In addition, gastric cancer had a strong influence on the microbial diversity of the stomach via enhancing the number of pathogens of Streptococcus, Peptostreptococcus and Prevotella, and reducing the percentage of the probiotic Bifidobacterium. Although partial gastrectomy markedly changed intestinal microbial diversity, the taking of the probiotic combination greatly reduced the ratio of Firmicutes/Bacteroidetes compared with patients taking no probiotics at the phylum level. At the genus level, the probiotic combination significantly enhanced the numbers of the probiotic bacteria Bacteroides, Faecalibacterium and Akkermansia and lowered the richness of Streptococcus. Therefore, we concluded that the taking of the probiotic combination significantly enhances the immune response of patients and reduces the severity of inflammation through modification of gut microbiota.

Revealing the Disturbed Vaginal Micobiota Caused by Cervical Cancer Using High-Throughput Sequencing Technology

“…Theαvalue was set to 0.05 in order to correct multiple comparisons. Finally, we used Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUST) to analyze the metabolic function and its influence on the host cell of bacteria in Kyoto Encyclopedia of Genes and Genomes (KEGG) functional spectrum database ( Liu et al., 2019 ; Zheng et al., 2019 ).…”

Antibiotics for cancer treatment: A double-edged sword

“…In our previous studies, orally taking of probiotics drugs during radiotherapy, chemotherapy and surgery in patients can significantly reduce their side effects by improving the disorder of intestinal microbiota 94 , 95 . Other works also indicated that dietary supplements (prebiotics) 96 or prebiotics 97 could selectively stimulate the growth and activity of internal probiotics to reduce the disorder of intestinal microbiota.…”

<p>Novel cancer therapy targeting microbiome</p>

“…Patients with colon cancer that received probiotics, Bifidobacterium lactis Bl-04 and Lactobacillus acidophilus NCFM had an increased abundance of butyrate-producing bacteria, especially Faecalibacterium and Clostridiales spp in the tumour, non-tumour mucosa and faecal microbiota, resulting in the reduction of colorectal cancer-associated genera such as Fusobacterium and Peptostreptococcus 71. Recent study showed that a probiotic combination containing Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis and Bacillus cereus reduced the physiological disorders induced by gastrectomy 72. Another randomized, double-blind, placebo-controlled trial showed that probiotics reduced the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma 73.…”